Improvements to Cancer Clinical Trials After COVID-19 Wreckage

November 3, 2020 3:00 pm

By Kate Johnson

As the COVID-19 pandemic rolled across North America earlier this year, cancer clinics shut their doors, patients stayed home, and oncology researchers contemplated an unthinkable setback as laboratory closures and trial freezes threatened the demise of years … Read more

The Stressful Conclusion of a Clinical Trial

October 29, 2020 9:00 am

By 

Does a pharmaceutical company have a moral obligation to acknowledge my participation with an ongoing supply of the product that I helped test?

When I learned this summer that the clinical trial of the cancer drug that … Read more

Most Cancer Patients Would Join a Clinical Trial if Offered the Chance

October 20, 2020 4:00 pm

By Anne Harding

New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials.

Overall, 55% of patients offered trial participation agreed to enroll, and white and Black patients agreed to … Read more

Large Genomics Study Points the Way to Future Cancer Clinical Trials

October 14, 2020 11:00 am

By Angus Liu

Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more

First-in-Human Study of RAF Family Kinase Inhibitor Lifirafenib in Solid Tumors

March 27, 2020 12:30 pm

By Matthew Stenger

In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or … Read more

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 26, 2020 10:00 am

By Jason M. Broderick

An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more